NCT06352424View on ClinicalTrials.gov

A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

February 24, 2025

Study Completion Date

February 24, 2025

Conditions
Obesity
Interventions
DRUG

BI 456906

BI 456906

DRUG

BI 1820237

BI 1820237

DRUG

Placebo for BI 1820237

Placebo for BI 1820237

DRUG

Placebo for BI 456906

Placebo for BI 456906

Trial Locations (1)

10117

Charité Research Organisation GmbH, Berlin

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT06352424 - A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity | Biotech Hunter | Biotech Hunter